Association Between CYP3A5 Polymorphisms and Blood Pressure in Kidney Transplant Recipients Receiving Calcineurin Inhibitors

REFERENCES

• Kasiske B, Vazquez M, Harmon W, Brown R, Danovitch G, Gaston R, . Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000;11 suppl 15:S1–86.
   PubMedGoogle Scholar
• Olyaei A, de Mattos A, Bennett W. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001;7:384–389.
   PubMedGoogle Scholar
• Luke R. Mechanism of cyclosporine-induced hypertension. Am J Hypertens 1991;4:468–471.
   PubMed Web of Science ®Google Scholar
• Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002;359:741–746.
   PubMed Web of Science ®Google Scholar
• Bochud M, Bovet P, Burnier M, Eap C. CYP3A5 and ABCB1 genes and hypertension. Pharmacogenomics 2009;10:477–487.
   PubMed Web of Science ®Google Scholar
• Guengerich F. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1–17.
   PubMed Web of Science ®Google Scholar
• Wilkinson G. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211–2221.
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383–391.
   PubMed Web of Science ®Google Scholar
• Kronbach T, Fischer V, Meyer U. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43:630–635.
   PubMed Web of Science ®Google Scholar
• Sattler M, Guengerich F, Yun C, Christians U, Sewing K. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753–761.
   PubMed Web of Science ®Google Scholar
• Macphee I, Fredericks S, Tai T, Syrris P, Carter N, Johnston A, Goldberg L, Holt DW. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002;74:1486–1489.
   PubMed Web of Science ®Google Scholar
• Thervet E, Anglicheau D, King B, Schlageter M, Cassinat B, Beaune P, Legendre C, Daly AK. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003;76:1233–1235.
   PubMed Web of Science ®Google Scholar
• Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo JJ, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–1252.
   PubMed Web of Science ®Google Scholar
• Menghetti E, Virdis R, Strambi M, Patriarca V, Riccioni M, Fossali E, Spagnolo A. Blood pressure in childhood and adolescence: the Italian normal standards. Study Group on Hypertension’ of the Italian Society of Pediatrics’. J Hypertens. 1999;17:1363–1372.
   PubMed Web of Science ®Google Scholar
• Cui J, Hopper J, Harrap S. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension 2003;41:207–210.
   PubMed Web of Science ®Google Scholar
• Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Schwartz G, Haycock G, Edelmann CJ, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259–263.
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004;78:1182–7.
   PubMed Web of Science ®Google Scholar
• Hjelmesaeth J, Hartmann A, Midtvedt K, Aakhus S, Stenstrøm J, Mørkrid L, Egeland T, Tordarson H, Fauchald P. Metabolic cardiovascular syndrome after renal transplantation. Nephrol Dial Transplant 2001;16:1047–1052.
   PubMed Web of Science ®Google Scholar
• Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998;53:217–222.
   PubMedGoogle Scholar
• First M, Neylan J, Rocher L, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 1994;4:S30–36.
   PubMed Web of Science ®Google Scholar
• Midtvedt K, Hartmann A. Hypertension after kidney transplantation: are treatment guidelines emerging? Nephrol Dial Transplant 2002;17:1166–1169.
   PubMed Web of Science ®Google Scholar
• Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, . Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997;283:1552–1562.
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990;38:207–213.
   PubMed Web of Science ®Google Scholar
• Gillam EM, Guo Z, Ueng YF, Yamazaki H, Cock I, Reilly PE, Hooper WD, Guengerich FP. Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 1995;317:374–384.
   PubMed Web of Science ®Google Scholar
• Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, . Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996;50:52–59.
   PubMed Web of Science ®Google Scholar
• Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G, Raucy J, Guzelian P, Gionela K, Watlington CO. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys 1992;294:206–214.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Basu A, Ghosh S, Hagley R, Kramer L, Schuetz J, Grogan WM, Guzelian P, Watlington CO. Renal and hepatic family 3A cytochromes P450 (CYP3A) in spontaneously hypertensive rats. Biochem Pharmacol 1995;50:49–54.
   PubMed Web of Science ®Google Scholar
• Watlington C, Kramer L, Schuetz E, Zilai J, Grogan W, Guzelian P, Gizek F, Schoolwerth AC. Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. Am J Physiol 1992;262:F927–31.
   PubMed Web of Science ®Google Scholar
• Bai J, Lesko L, Burckart G. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors. Pharmacotherapy 2010;30:195–209.
   PubMed Web of Science ®Google Scholar
• Givens R, Lin Y, Dowling A, Thummel K, Lamba J, Schuetz E, . CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003;95:1297–1300.
   PubMed Web of Science ®Google Scholar
• Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC, Cadman P, O’Connor DT, Wagner U, Fineberg NS, Weinberger MH. Association between the CYP3A5 genotype and blood pressure. Hypertension 2005;45:294–8.
   PubMed Web of Science ®Google Scholar
• Kivistö K, Niemi M, Schaeffeler E, Pitkälä K, Tilvis R, Fromm M, Guzelian P, Gizek F, Schoolwerth AC. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study. Am J Pharmacogenomics 2005;5:191–195.
   PubMedGoogle Scholar
• Kreutz R, Zuurman M, Kain S, Bolbrinker J, de Jong P, Navis G. The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet Genomics 2005;15:831–837.
   PubMed Web of Science ®Google Scholar
• Eap C, Bochud M, Elston R, Bovet P, Maillard M, Nussberger J, Guzelian P, Gizek F, Schoolwerth AC. CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. Hypertension 2007;49:1007–1014.
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271–1294.
   PubMed Web of Science ®Google Scholar
• Langaee TY, Gong Y, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther 2007;81:386–391.
   PubMed Web of Science ®Google Scholar
• Bochud M, Eap C, Elston R, Bovet P, Maillard M, Schild L, Shamlaye C, Burnier M. Association of CYP3A5 genotypes with blood pressure and renal function in African families. J Hypertens 2006;24:923–929.
   PubMed Web of Science ®Google Scholar
• Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, . CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 2005;33:884–887.
   PubMed Web of Science ®Google Scholar
• Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmöller J, Halpert JR, Zanger UM, Wojnowski L. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773–779.
   PubMedGoogle Scholar
• Catarsi P, Ravazzolo R, Emma F, Fruci D, Finos L, Frau A, Morreale G, Carrea A, Ghiggeri GM. Angiotensin-converting enzyme (ACE) haplotypes and cyclosporine A (CsA) response: a model of the complex relationship between ACE quantitative trait locus and pathological phenotypes. Hum Mol Genet 2005;14:2357–2367.
   PubMed Web of Science ®Google Scholar
• Basset e-E, Berthoux P, Cécillon S, Deprle C, Thibaudin D, De Filippis JP, Alamartin E, Berthou F. Hypertension after renal transplantation and polymorphism of genes involved in essential hypertension: ACE, AGT, AT1 R and ecNOS. Clin Nephrol 2002;57:192–200.
   PubMed Web of Science ®Google Scholar
• Moe KT, Lim ST, Wong P, Chua T, DeSilva DA, Koh TH, Wong MC, Chin-Dusting J. Association analysis of endothelial nitric oxide synthase gene polymorphism with primary hypertension in a Singapore population. J Hum Hypertens 2006;20:956–963.
   PubMed Web of Science ®Google Scholar
• Calò L, Semplicini A, Davis PA, Bonvicini P, Cantaro S, Rigotti P, D’Angelo A, Livi U, Antonello A. Cyclosporin-induced endothelial dysfunction and hypertension: are nitric oxide system abnormality and oxidative stress involved? Transpl Int 2000;13 suppl 1:S413–418.
   PubMedGoogle Scholar
• Ferraresso M, Tirelli A, Ghio L, Grillo P, Martina V, Torresani E, Edefonti A. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant 2007;11:296–300.
   PubMed Web of Science ®Google Scholar
• Thervet E, Anglicheau D, Legendre C, Beaune P. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit 2008;30:143–150.
   PubMed Web of Science ®Google Scholar
• Picard N, Cresteil T, Prémaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004;26:600–608.
   PubMed Web of Science ®Google Scholar
• Lévesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, Guillemette C. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007;81:392–400.
   PubMed Web of Science ®Google Scholar
• Rendic S, Di Carlo F. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:413–580.
   PubMed Web of Science ®Google Scholar
• Ma X, Idle J, Gonzalez F. The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol 2008;4:895–908.
   PubMed Web of Science ®Google Scholar
• Zhang B, Xie W, Krasowski M. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 2008;9:1695–1709.
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Flamant M, Schlageter M, Martinez F, Cassinat B, Beaune P, Legendre C, Thervet E. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003;18:2409–2414.
   PubMed Web of Science ®Google Scholar
• Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour D, Malaise J, Lison D, Squifflet JP, Wallemacq P. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004;14:147–154.
   PubMedGoogle Scholar